Long-term survival outcomes with Nivolumab (Nivo) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

被引：0

作者：

Wohlleber, M. ^{[1
]}

Brahmer, J. ^{[2
]}

Borghaei, H. ^{[3
]}

Ramalingam, S. S. ^{[4
]}

Horn, L. ^{[5
]}

de Castro Carpeno, J. ^{[6
]}

Pluzanski, A. ^{[7
]}

Burgio, M. A. ^{[8
]}

Garassino, M. ^{[9
]}

Chow, L. Q. M. ^{[10
]}

Gettinger, S. ^{[11
]}

Crino, L. ^{[7
]}

Planchard, D. ^{[12
]}

Butts, C. ^{[13
]}

Drilon, A. ^{[14
]}

Wojcik-Tomaszewska, J. ^{[15
]}

Otterson, G. ^{[16
]}

Agrawal, S. ^{[17
]}

Li, A. ^{[17
]}

Penrod, J. R. ^{[17
]}

Antonia, S. J. ^{[18
]}

机构：

[1] Robert Bosch Ctr Tumorerkankungen RBCT, Dept Pneumol Oncol, Gerlingen, Germany

[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Ctr Integral Oncol Clara Campal, Madrid, Spain

[7] Inst Marii Sklodowskiej Curie, Ctr Onkol, Klin Nowotworow Pluca & Klatki Piersiowej, Warsaw, Poland

[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Med Oncol Unit, Meldola, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[10] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA

[11] Yale Canc Ctr, New Haven, CT USA

[12] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[13] Cross Canc Inst, Dept Oncol, Div Med Oncol, Edmonton, AB, Canada

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[15] Wojewodzkie Ctr Onkol, Gdansk, Poland

[16] Ohio State Univ, Columbus, OH 43210 USA

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P406

引用

页码：110 / 110

页数：1

共 50 条

[1] Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
Brahmer, J.
Horn, L.
Hossein, B.
Ramalingam, S.
Pluzanski, A.
Burgio, M. A.
Garassino, M. C.
Chow, L. Q. M.
Gettinger, S.
Crino, L.
Planchard, D.
Butts, C.
Drilon, A.
Wojcik-Tomaszewska, J.
Otterson, G.
Agrawal, S.
Li, A.
Penrod, J. R.
Antonia, S. J.
Bautista, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1152 - S1153
[2] Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response
Brahmer, Julie
Borghaei, Hossein
Ramalingam, Suresh S.
Horn, Leora
Holgado, Esther
Pluzanski, Adam
Burgio, Marco A.
Garassino, Marina
Chow, Laura Q.
Gettinger, Scott
Crino, Lucio
Planchard, David
Butts, Charles
Drilon, Alexander
Wojcik-Tomaszewska, Joanna
Otterson, Gregory
Hayreh, Vinny
Li, Ang
Penrod, John R.
Antonia, Scott J.
[J]. CANCER RESEARCH, 2019, 79 (13)
[3] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
Thomas, M.
Kohlhaeufl, M.
Reck, M.
Engel-Riedel, W.
Kortsik, C.
Bullinger, L.
Schneider, C. -P.
Felip, E.
Brahmer, J.
Vokes, E.
Gettinger, S.
Geese, W.
Yoon, D.
Healey, D.
Li, A.
Eberhardt, W. E. E.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
[4] Long-term survivorship for patients with non-small cell lung cancer (NSCLC) treated with nivolumab (nivo): a response-based modeling approach
Snider, J. Thornton
Ward, A. Sexton
Penrod, J. R.
Dastani, H.
Yuan, Y.
Van Eijndhoven, E.
Figlin, R. A.
Chandra, A.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S135 - S136
[5] Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Costantini, Adrien
Corny, Jennifer
Fallet, Vincent
Renet, Sophie
Friard, Sylvie
Chouaid, Christos
Duchemann, Boris
Giroux-Leprieur, Etienne
Taillade, Laurent
Doucet, Ludovic
Nguenang, Marina
Jouveshomme, Stephane
Wislez, Marie
Tredaniel, Jean
Cadranel, Jacques
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[6] Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab
Murakami, Yusuke
Tamiya, Akihiro
Taniguchi, Yoshihiko
Adachi, Yuichi
Enomoto, Takatoshi
Azuma, Koji
Inagaki, Yuji
Kouno, Shunichi
Matsuda, Yoshinobu
Okishio, Kyoichi
Atagi, Shinji
[J]. THORACIC CANCER, 2022, 13 (04) : 593 - 601
[7] Long-term survival in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab
Topalian, Suzanne L.
Hodi, F. Stephen
Brahmer, Julie R.
Gettinger, Scott N.
Smith, David C.
McDermott, David F.
Powderly, John D.
Sosman, Jeffrey A.
Atkins, Michael B.
Spigel, David R.
Antonia, Scott J.
Drilon, Alexander
Bhore, Rafia
Hosein, Fareeda
Sznol, Mario
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[8] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Costantini, Adrien
Julie, Catherine
Dumenil, Coraline
Helias-Rodzewicz, Zofia
Dumoulin, Jennifer
Giraud, Violaine
Labrune, Sylvie
Chinet, Thierry
Emile, Jean-Francois
Giroux-Leprieur, Etienne
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[9] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rogado, J.
Pacheco-Barcia, V.
Fenor De la Maza, M. D.
Serra, J. M.
Toquero, P.
Vera, B.
Obispo, B.
Mondejar, R.
Ballesteros, A.
Donnay, O.
Colomer, R.
Sanchez-Torres, J. M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
[10] Overall Analysis shows Data on Long-term Survival with Nivolumab in previously treated Patients with non-small cell Lung Carcinoma
不详
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) : 301 - 301

← 1 2 3 4 5 →